. "* 36 - 28 mL/h [SC doses ranging from 10 to 20 mg/day]"@en . . . . . . . . . . . "* 7 L"@en . "~6 days"@en . . "Mandayam J. Narasimhan, John A. Anderson, \"Process for the large scale production of human growth hormone by serial secondary suspension culture.\" U.S. Patent US4124448, issued January, 1963."@en . "Growth hormone"@en . . . "Pituitary growth hormone"@en . "GH"@en . . . "Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity."@en . "Growth hormone 1"@en . "approved"@en . . . . "Pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly."@en . "GH-N"@en . "Pegvisomant"@en . "218620-50-9"@en . "Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH. This leads to the normalization of serum IGF-1 levels."@en . "Humans and other mammals"@en . . . " "@en . . . "Somatotropin precursor"@en . . . . . . . . . . .